title: Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis.
abstract: OBJECTIVE
  We performed a propensity score matched analysis to explore whether TiNOX stents are superior to paclitaxel- (PES) and sirolimus-eluting stents (SES) in routine clinical practice.
  
  
  RESULTS
  A total of 1,607 patients undergoing implantation of SES, PES or TiNOX stents were prospectively entered into a stent registry and followed up for three years. Using propensity score matching, we compared clinical outcome among 319 pairs of patients treated with TiNOX stents or SES and 337 pairs of patients treated with TiNOX stents or PES. The primary outcome MACE, a composite of death, myocardial infarction, and target vessel revascularisation occurred in 20% of patients with TiNOX stents, 19% of patients with SES and 23% of patients with PES at 3-years. The hazard ratio was 1.00 comparing TiNOX stents with SES (95% CI 0.69-1.45, p=1.00), and 0.95 comparing TiNOX stents with PES (95% CI 0.66-1.36, p=0.78).
  
  
  CONCLUSIONS
  We did not find evidence to suggest superiority of TiNOX stents over SES or PES. In view of similar clinical outcomes, but with the reduced duration of dual antiplatelet therapy used with the TiNOX stent, we suggest that TiNOX stents may be an alternative to drug-eluting stents in patients unsuitable for long-term dual antiplatelet therapy.
authors.affiliation: CTU Bern, Bern University Hospital, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Limacher
authors.forename: Lorenz
authors.initials: L
authors.lastname: Räber
authors.forename: Eva
authors.initials: E
authors.lastname: Laube
authors.forename: Annette
authors.initials: A
authors.lastname: Lauterburg
authors.forename: Sylvan
authors.initials: S
authors.lastname: Lötscher
authors.forename: Nina
authors.initials: N
authors.lastname: Hess
authors.forename: Aris
authors.initials: A
authors.lastname: Moschovitis
authors.forename: Samuel H
authors.initials: SH
authors.lastname: Baldinger
authors.forename: Peter
authors.initials: P
authors.lastname: Wenaweser
authors.forename: Bernhard
authors.initials: B
authors.lastname: Meier
authors.forename: Otto M
authors.initials: OM
authors.lastname: Hess
authors.forename: Peter
authors.initials: P
authors.lastname: Jüni
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000075202:Contraindications; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel; D010975:Platelet Aggregation Inhibitors; D057216:Propensity Score; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control; D014025:Titanium; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; C434243:titanium-nitride-oxide; D014025:Titanium; D017239:Paclitaxel; D020123:Sirolimus